Clinical Trial Update: A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease [Phase 3]

View source ↗

Summary

Phase 3 study comparing ATB200/AT2221 with alglucosidase alfa/placebo in adults with late-onset Pompe disease has completed, with results posted in September 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• ATB200/AT2221
• Alglucosidase alfa (alglucosidase alfa)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease (Late-onset) | Phase 3 | Status: COMPLETED | Results posted: 2023-09-11